Celcuity Inc. Files Definitive Proxy Statement

TL;DR

Celcuity Inc. filed its DEF 14A. No fee. Annual meeting stuff.

AI Summary

Celcuity Inc. filed a definitive proxy statement (DEF 14A) on August 28, 2024. The filing pertains to the company's annual meeting and does not involve a fee. Celcuity Inc. is a medical laboratory services company incorporated in Delaware with its principal business address in Minneapolis, MN.

Why It Matters

This filing is a standard regulatory requirement for public companies, informing shareholders about upcoming meetings and voting matters.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial information or strategic changes.

Key Players & Entities

• Celcuity Inc. (company) — Registrant
• 0001493152-24-034185 (filing_id) — Accession Number
• August 28, 2024 (date) — Filing Date
• Minneapolis, MN (location) — Business Address

FAQ

Key Financial Figures

• $0.001 — rized number of shares of common stock, $0.001 par value per share (“Common Stoc
• $9.77 — options at a weighted average price of $9.77 per share; 3,175,770 shares of Common
• $3,378,480 — ommon Stock issuable upon conversion of $3,378,480 of outstanding principal under the Comp
• $10.00 — eement”) at a conversion price of $10.00 per share; 5,590,048 shares of Common
• $8.25 — th a weighted average exercise price of $8.25 per share; 5,747,787 shares of Common

Filing Documents

• formdef14a.htm (DEF 14A) — 164KB
• image_001.jpg (GRAPHIC) — 322KB
• image_002.jpg (GRAPHIC) — 324KB
• 0001493152-24-034185.txt ( ) — 1055KB

Business

Business Our Board currently has no knowledge of any matters to be presented at the Special Meeting other than those referred to in this Proxy Statement. The solicited proxies give discretionary authority to the proxy agents named therein to vote in accordance with the recommendation of the Board if any other matters are presented. Interest of Officers and Directors in Matters to Be Acted Upon None of our officers or directors have any interest in any of the matters to be acted upon at the Special Meeting. 4 PROPOSAL 1 APPROVAL OF AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF OUR COMMON STOCK Our Board has adopted, subject to stockholder approval, an amendment to our Certificate of Incorporation to increase the number of authorized shares of our Common Stock from 65,000,000 shares to 95,000,000 shares. The form of the proposed amendment to the Certificate of Incorporation is attached as Appendix A to this Proxy Statement. The discussion below is qualified in its entirety by reference to the actual text of the proposed amendment as set forth in Appendix A. This proposal is referred to in this Proxy Statement as the “Authorized Share Increase” or “Proposal 1.” Current Capitalization Our Certificate of Incorporation currently authorizes the issuance of up to 67,500,000 shares of capital stock, including up to 65,000,000 shares of Common Stock and 2,500,000 shares of preferred stock, $0.001 par value per share, of which 1,850,000 shares have been designated as Series A Convertible Preferred Stock (the “Series A Preferred Stock”). As of August 9, 2024, 37,030,155 shares of our Common Stock were issued and outstanding; and 20,754,742 shares of Common Stock were reserved for issuance as described below: 3,462,739 shares of Common Stock issuable upon exercise of outstanding options at a weighted average price of $9.77 per share; 3,175,770 shares of Common Stock issu

View Full Filing

View this DEF 14A filing on SEC EDGAR